News
![News 1030](/media/tmllr1t5/news_1030.jpg?center=0.065323897659227,0.53618276172421053&mode=crop&width=1030&height=302&rnd=133034831402870000)
World Brain Day is a global initiative that occurs annually on 22nd July and is dedicated to raising awareness of the importance of Brain Health and advancing education on neurological diseases.
Identifying new options to increase adherence is vital to the epilepsy community.
Angelini Pharma is proud to announce its participation in the European Academy of Neurology Congress 2024 (EAN), representing Europe’s largest forum for Neurology.
"Heat therapy, a practice that has stood the test of time, offers practical benefits for a variety of musculoskeletal conditions, making it a valuable tool in our field", Prof. Jürgen Freiwald.
Today, May 20th, marks a significant occasion for the medical research community: it’s Clinical Trials Day. Sponsored by the Association of Clinical Research Professionals (ACRP), this event pays tribute to the dedicated scientists and researchers who drive medical progress through clinical trials.
Neurological disorders affect 43.1% of the global population. In this regard, epilepsy continues to be among top 10 most impactful neurological disorders.
This significant achievement underscores the company's ongoing dedication to minimizing the environmental impact of its laboratory space.
Brain Awareness Week was originally created by the Dana Alliance for Brain Initiatives in 1995 to raise public awareness about the advancements and benefits of brain research.
Angelini Pharma's participation in the #50MILLIONSTEPS challenge is part of a broader commitment by the company in the fight against epilepsy, a condition affecting fifty million people worldwide.
Angelini Pharma celebrates the event through the words of its researchers.